| CLARX | VGSLX | CLARX / VGSLX | |
| Total Expense Ratio | 1.18 | 0.13 | 908% |
| Annual Report Gross Expense Ratio | 1.39 | 0.13 | 1,069% |
| Fund Existence | 23 years | 24 years | - |
| Gain YTD | 1.019 | 5.500 | 19% |
| Front Load | 6% | N/A | - |
| Min. Initial Investment | 15000 | 3000 | 500% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 224M | 64B | 0% |
| Annual Yield % from dividends | 2.66 | 3.86 | 69% |
| Returns for 1 year | -6.43 | -3.18 | 202% |
| Returns for 3 years | -19.74 | 18.09 | -109% |
| Returns for 5 years | -5.10 | 31.11 | -16% |
| Returns for 10 years | -44.35 | 63.23 | -70% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AZTD | 28.44 | N/A | N/A |
| Aztlan Global Stock Sel Dm SMID ETF | |||
| SPEM | 47.02 | -0.01 | -0.02% |
| SPDR® Portfolio Emerging Markets ETF | |||
| XMAR | 39.62 | -0.02 | -0.04% |
| FT Vest U.S. Eq Enh & ModBufETF-Mar | |||
| CARY | 20.91 | -0.03 | -0.13% |
| Angel Oak Income ETF | |||
| THNR | 25.43 | -0.79 | -3.00% |
| Amplify Weight Loss Drug & Treatment ETF | |||